Last reviewed · How we verify

Kedrion S.p.A. — Portfolio Competitive Intelligence Brief

Kedrion S.p.A. pipeline: 1 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Kedbumin 25% Kedbumin 25% marketed Plasma protein fraction / Human serum albumin Critical Care / Hematology
Coagadex(R) Coagadex(R) phase 3 Recombinant clotting factor Factor X (coagulation factor X) Hematology
Kedrion IVIG 10% Kedrion IVIG 10% phase 3 Intravenous immunoglobulin (IVIG) Multiple (polyvalent IgG; Fc receptors; complement system) Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Baxalta now part of Shire · 2 shared drug classes
  2. Octapharma · 2 shared drug classes
  3. Bio Products Laboratory · 1 shared drug class
  4. Bioverativ Therapeutics Inc. · 1 shared drug class
  5. CSL Behring · 1 shared drug class
  6. CSL Limited · 1 shared drug class
  7. Capital Medical University · 1 shared drug class
  8. Biotest · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Kedrion S.p.A.:

Cite this brief

Drug Landscape (2026). Kedrion S.p.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kedrion-s-p-a. Accessed 2026-05-16.

Related